Royal Oak, MINCT06709521Now EnrollingIRB Ready

Gram-negative infection Clinical Trial in Royal Oak, MI

Access cutting-edge gram-negative infection treatment through this clinical trial at a research site in Royal Oak. Study-provided care at no cost to qualified participants.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)

Quick Self-Assessment

See if you qualify for this Royal Oak location

Preparing your pre-screening questions...

Expert Care in Royal Oak

Access gram-negative infection specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gram-negative infection treatment provided free

Apply for This Royal Oak Location

Check if you qualify for this gram-negative infection clinical trial in Royal Oak, MI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Royal Oak

    Convenient for MI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Royal Oak site if eligible
  4. 4Begin participation

About This Gram-negative infection Study in Royal Oak

The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Who Can Participate

Inclusion Criteria

Age \>/=18 years at the time of enrollment. 2. Residing in an ICU. 3. Documented or suspected Antimicrobial Resistant (AMR) Gram-negative infection for which the prospective participant is receiving meropenem or cefepime as part of their clinical management. 4. Expectation that the prospective participant will reside in the ICU and receive meropenem or cefepime for the duration of the study, and that all study procedures will be completed. 5. Expectation that IV access will be sufficient for drug infusion and either IV or arterial access will be sufficient to allow for all protocol-required blood sampling to occur. 6. The prospective participant, or their legally authorized representative (LAR), is able and willing to provide signed informed consent

Exclusion Criteria

Prospective participant has a documented hypersensitivity or allergic reaction to iohexol, any contrast agents, or iodine. 2. Prospective participant has a documented prior history of severe

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Royal Oak?

Yes, this clinical trial (NCT06709521) has an active research site in Royal Oak, MI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gram-negative infection Treatment Options in Royal Oak, MI

If you're searching for gram-negative infection treatment options in Royal Oak, MI, this clinical trial (NCT06709521) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Royal Oak research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gram-negative infection specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gram-negative infection clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Royal Oak, MI

See all rheumatoid arthritis clinical trials recruiting in Royal Oak — not just this study.

Browse Rheumatoid Arthritis Trials in Royal Oak →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsGeographic Atrophy TrialsAll Conditions →

Ready to Join in Royal Oak?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Royal Oak, MI